Table 1 Clinical characteristics for patients with ankylosing spondylitis participating in the study (n = 210)
From: Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study
Age (years) | 49 (13) |
Men/Women | 120/90 |
BMI | 26.0 (4.5) |
Smoker ≥ 6 months | 105 (50%) |
Rheumatologic characteristics | |
Age at symptom onset (years) | 26 (10) |
Symptom duration (years) | 24 (13) |
Diagnostic age (years) | 36 (11) |
Diagnostic duration (years) | 14 (11) |
BASDAI (score) | 3.6 (2.1) |
BASFI (score) | 2.7 (2.1) |
BASMI (score) | 3.1 (1.6) |
Blood tests | |
HLA B27 n (%) | 183* (87) |
Hemoglobin (g/L) | 139 (13) |
White blood cell count (×109/L) | 7.0 (2.2) |
Platelet count (×109/L) | 298 (75) |
Erythrocyte sedimentation rate (mm/h) | 15 (14) |
C-reactive protein (mg/L) | 8.4 (10.2) |
Concomitant diseases | |
Diabetes mellitus | 6 (2.9) |
Hyperlipidemia | 17 (8.1) |
Hypertension | 56 (27) |
Other cardiovascular diseases¶ | 26 (12) |
Coronary artery disease | 6 (2.9) |
Heart failure | 4 (1.9) |
Valvular disease | 6 (2.9) |
Arrhythmia | 4 (1.9) |
Various not specified/ | 10 (4.8) |
Stroke | 4 (1.9) |
Medication | |
ACEI/ARB | 23 (11) |
Analgesics | 54 (26) |
Antiarrhythmic agents | 3 (1.4) |
Antidiabetic agents | 3 (1.4) |
Antihypertensive agents | 15 (7.1) |
ASA | 22 (11) |
Betablockers | 28 (13) |
Calcium antagonists | 7 (3.3) |
Digitalis | 2 (1.0) |
Diuretics | 15 (7.1) |
DMARD | 77 (37) |
Lipid modulators | 15 (7.1) |
NSAID | 161 (77) |
TNF inhibitor | 45 (21) |
Warfarin | 2 (1.0) |